Credit Suisse’s LENZ Therapeutics LENZ Stock Holding History

Credit Suisse’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2	Closed	–	–	4344
2022 Q2	$0	Buy	+2	New	+$45	﹤0.01%	4377

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Credit Suisse's LENZ Position: Q3 2022 in Review

Credit Suisse sold out of LENZ Therapeutics (LENZ) in Q3 2022, closing a stake of 2 shares.

Credit Suisse first reported a position in LENZ in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 63 funds tracked by Wall St. Rank hold LENZ as of Q3 2022.

Credit Suisse reported no remaining LENZ Therapeutics position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 2 LENZ Therapeutics shares in Q3 2022.
Credit Suisse first reported a position in LENZ Therapeutics in Q2 2022 and held it in 1 quarter.
Credit Suisse's LENZ Therapeutics position peaked at $0 in Q2 2022.
63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.